‘How to’ – Stability Studies

Dermatological products, including creams, ointments, gels, and lotions, require specific stability testing to ensure their safety, efficacy, and quality. These products are often sensitive to environmental factors such as light, temperature, and humidity, making rigorous stability testing essential. This guide outlines the steps to conduct stability studies for dermatological products in compliance with regulatory guidelines from authorities such as the US FDA, EMA, and WHO.
Click to read the full article.

The FDA’s Quality by Design (QbD) approach emphasizes building quality into pharmaceutical products through a systematic understanding of processes and product characteristics. Preparing stability data under the QbD framework involves integrating stability considerations into the product development process to ensure consistent quality, safety, and efficacy. This guide outlines the steps to prepare stability data in compliance with the FDA’s QbD approach.
Click to read the full article.

The ICH Q8 guideline, “Pharmaceutical Development,” emphasizes a systematic approach to development that ensures product quality through design, understanding, and control of manufacturing processes. Implementing ICH Q8 principles in stability testing helps to optimize product formulation and ensure consistent quality. This guide outlines how to apply ICH Q8 for stability testing in pharmaceutical development, ensuring regulatory compliance and quality control.
Click to read the full article.

Modified-release formulations, such as extended-release, delayed-release, and controlled-release products, are designed to release their active ingredients over a specific period. Stability testing for these formulations is critical to ensure they maintain their intended release profile, safety, efficacy, and quality throughout their shelf life. This guide outlines the steps to conduct stability testing for modified-release formulations in compliance with regulatory guidelines from authorities like the US FDA, EMA, and WHO.
Click to read the full article.

ICH Q10, the Pharmaceutical Quality System guideline, provides a comprehensive framework for maintaining and improving the quality of pharmaceutical products throughout their lifecycle. Applying ICH Q10 principles to stability studies helps ensure consistent product quality and regulatory compliance. This guide outlines how to integrate ICH Q10 into stability testing processes to enhance pharmaceutical quality systems.
Click to read the full article.

Drugs with complex Active Pharmaceutical Ingredients (APIs), such as peptides, proteins, and other large molecules, pose unique challenges in stability testing due to their susceptibility to degradation and structural changes. Regulatory authorities, including the US FDA, EMA, and WHO, provide specific guidelines for conducting stability studies on drugs with complex APIs. This guide outlines the steps to ensure compliance with these guidelines.
Click to read the full article.

Drug products intended for distribution in tropical and subtropical regions face unique challenges due to high temperatures and humidity levels that can affect their stability. The ICH Q1A(R2) guideline provides a framework for conducting stability testing in these environments, ensuring product quality, safety, and efficacy. This guide outlines the steps to implement ICH Q1A(R2) for stability testing in tropical and subtropical regions.
Click to read the full article.

Drug products with multiple active ingredients, such as combination therapies, require thorough stability testing to ensure that each ingredient remains stable and maintains its intended efficacy and safety throughout the product’s shelf life. Regulatory authorities, including the US FDA, EMA, and WHO, provide specific guidelines for stability testing of these complex formulations. This guide outlines the steps to address stability testing requirements for drug products with multiple active ingredients under these regulatory guidelines.
Click to read the full article.

Novel excipients are substances not previously used in approved drug products, often introduced to enhance formulation properties or delivery of the active drug. Stability testing for drug products containing novel excipient-drug combinations is essential to ensure safety, efficacy, and quality. Regulatory authorities such as the FDA, EMA, and WHO provide guidelines for conducting stability studies on these unique formulations. This guide outlines the steps to conduct stability studies for novel excipient-drug combinations in compliance with regulatory requirements.
Click to read the full article.

Drug products must meet specific stability requirements to ensure safety, efficacy, and quality across different regions. Various regulatory authorities, such as the US FDA, EMA, and other regional agencies, have distinct guidelines for stability testing. Implementing stability testing in compliance with these regional regulatory requirements is crucial for market approval. This guide outlines the steps to conduct stability testing for drug products according to different regional regulatory requirements.
Click to read the full article.